← Back to Calendar

Rhythm Pharmaceuticals Q1 2026 Earnings

Rhythm Pharmaceuticals · $RYTM

Standard Review Earnings

PDUFA Date

May 8, 2026

Time Remaining

45 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + acquired HO commercial launch update

Key Notes

Q1 2026 earnings expected ~May 2026. IMCIVREE acquired HO PDUFA March 20, 2026 — if approved, Q1 earnings will include early launch data. EMA CHMP opinion expected Q2 2026. EMANATE Phase 3 topline data expected early 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar